New Philips–Cortechs.ai Collaboration Strengthens Precision Brain Diagnostics with Automated MR Analytics

New Philips–Cortechs.ai Collaboration Strengthens Precision Brain Diagnostics with Automated MR Analytics

(IN BRIEF) Philips has expanded its partnership with Cortechs.ai to integrate the company’s AI-driven neuroimaging analytics directly into Philips’ MR systems, enabling clinicians to receive automated quantitative brain measurements within the standard MR workflow. The collaboration aims to improve diagnostic accuracy, reproducibility, and efficiency as neurological conditions continue to rise and radiology departments face ongoing workforce shortages. Through tools such as volumetric analysis, lesion quantification, and tumor tracking, the integration supports faster, more objective assessments of conditions like Alzheimer’s disease, multiple sclerosis, and brain tumors. Combined with Philips’ Smart Reading AI platform, the workflow will generate quality-checked reports automatically, streamlining interpretation and reducing manual post-processing. Leaders from both organizations emphasize that this extension advances the shift toward precision neuroimaging and supports clinicians in delivering more personalized, data-driven neurological care.

(PRESS RELEASE) AMSTERDAM, 19-Nov-2025 — /EuropaWire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced an expanded strategic partnership with Cortechs.ai, the neuroimaging AI specialist known for its quantitative analysis solutions. Through this strengthened collaboration, Cortechs.ai’s advanced AI-powered neuroimaging tools will be integrated directly into Philips’ MR systems¹, giving clinicians access to consistent, data-driven insights that enhance the assessment of neurological conditions. The partnership enhances Philips’ position in precision neuro diagnostics by combining its next-generation MR technologies with Cortechs.ai’s automated post-processing capabilities to support earlier detection, improved monitoring, and more personalized management of brain diseases.

Across healthcare systems, up to a quarter of all MR scans focus on the brain², and radiology teams continue to face rising demand alongside widespread workforce shortages. At the same time, the incidence of Alzheimer’s disease, multiple sclerosis (MS), brain tumors, and other neurological disorders is increasing globally. Traditional MR interpretation relies heavily on visual review, which can vary by practitioner and requires significant expertise and time. Philips and Cortechs.ai aim to help address these challenges by embedding quantitative tools—such as automated brain volumetrics, lesion burden analysis, and tumor measurement—directly into the MR workflow, providing objective numerical data alongside imaging.

This expanded partnership centers around the integration of Cortechs.ai’s NeuroQuant® solutions for Alzheimer’s, MS, and neuro-oncology applications within Philips’ Smart Reading ecosystem, a cloud-based AI platform that unifies imaging, reading, and reporting directly on Philips MR systems¹. With the new workflow, quantitative reports are generated automatically during the MR exam and delivered directly on the MR system or PACS with no additional steps for technologists. This zero-click approach ensures quality-checked, standardized data, enabling radiologists to make more confident, faster, and more reproducible clinical decisions.

Ioannis Panagiotelis, PhD, Business Leader for MRI at Philips, emphasized that the partnership accelerates the shift toward AI-enabled neuroimaging: “By extending our partnership with Cortechs.ai, we are accelerating the transition to fully quantitative, AI-powered neuroimaging. This integration brings precision, reproducibility, and efficiency to neurological MR, helping clinicians make faster, more confident decisions for patients living with complex brain conditions.”

The collaboration supports Philips’ broader commitment to embedding AI throughout the diagnostic pathway—from addressing workforce pressures to providing more robust clinical insights. Automated quantitative biomarkers help reduce manual review time, standardize interpretation across sites, and strengthen diagnostic accuracy. By minimizing the need for manual post-processing and streamlining workflows, technologists can spend more time supporting patients during MR examinations.

Kyle Frye, CEO of Cortechs.ai, noted that the company’s mission aligns closely with the goals of the partnership: “Cortechs.ai’s mission has always been to empower clinicians with actionable, quantitative insights. By combining our advanced neuro analytics with Philips’ leading MR platform and AI infrastructure, we’re making it easier to personalize brain care and track neurological changes with precision.”

NeuroQuant® tools are already accessible through Philips’ Advanced Visualization Workspace, and this expanded partnership brings the two companies even closer toward establishing a new standard in precision neuro diagnostics. Together, Philips and Cortechs.ai aim to ensure that radiologists and neurologists can deliver more consistent, efficient, and patient-centered care for individuals living with neurological disorders.

¹ Integration via Smart Reading is a work in progress and not yet available in any jurisdiction. Future availability cannot be guaranteed.
² Source: Peter A. Rinck, Magnetic Resonance in Medicine – The Basics (14th ed., revised 2025).

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Cortechs.ai

Cortechs.ai is a leader in AI applications in radiology. Cortechs.ai uses cutting-edge technologies in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, healthier lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer. Cortechs.ai’s industry-leading brain imaging software provides radiologists, neurologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective way to quantify brain structures for assessing Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and other brain abnormalities. The company has FDA-cleared products for use in helping the diagnosis and follow-up of neurodegenerative and traumatic brain conditions, as well as prostate cancer. Please visit www.cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook.

Media Contact:

Jayme Maniatis
Philips Global External Relations
Contact details

Cortechs.ai
Tel.: +1 858 459 9700
E-mail: info@cortechs.ai

SOURCE: Philips